JP2023554524A5 - - Google Patents

Info

Publication number
JP2023554524A5
JP2023554524A5 JP2023537995A JP2023537995A JP2023554524A5 JP 2023554524 A5 JP2023554524 A5 JP 2023554524A5 JP 2023537995 A JP2023537995 A JP 2023537995A JP 2023537995 A JP2023537995 A JP 2023537995A JP 2023554524 A5 JP2023554524 A5 JP 2023554524A5
Authority
JP
Japan
Prior art keywords
group
combination therapy
use according
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023537995A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023554524A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/062115 external-priority patent/WO2022137125A1/en
Publication of JP2023554524A publication Critical patent/JP2023554524A/ja
Publication of JP2023554524A5 publication Critical patent/JP2023554524A5/ja
Pending legal-status Critical Current

Links

JP2023537995A 2020-12-22 2021-12-21 非アルコール性脂肪性肝炎の治療のための酸素含有構造強化脂肪酸を含む組合せ療法 Pending JP2023554524A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063128996P 2020-12-22 2020-12-22
US63/128,996 2020-12-22
PCT/IB2021/062115 WO2022137125A1 (en) 2020-12-22 2021-12-21 Combination therapies comprising oxygen-containing structurally enhanced fatty acids for treatment of non-alcoholic steatohepatitis

Publications (2)

Publication Number Publication Date
JP2023554524A JP2023554524A (ja) 2023-12-27
JP2023554524A5 true JP2023554524A5 (cg-RX-API-DMAC7.html) 2024-12-26

Family

ID=79283090

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023537995A Pending JP2023554524A (ja) 2020-12-22 2021-12-21 非アルコール性脂肪性肝炎の治療のための酸素含有構造強化脂肪酸を含む組合せ療法

Country Status (9)

Country Link
US (1) US20240325336A1 (cg-RX-API-DMAC7.html)
EP (1) EP4267124A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023554524A (cg-RX-API-DMAC7.html)
KR (1) KR20230128307A (cg-RX-API-DMAC7.html)
CN (1) CN116829139A (cg-RX-API-DMAC7.html)
AU (1) AU2021405273A1 (cg-RX-API-DMAC7.html)
CA (1) CA3201254A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023007347A (cg-RX-API-DMAC7.html)
WO (1) WO2022137125A1 (cg-RX-API-DMAC7.html)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009061208A1 (en) 2007-11-09 2009-05-14 Pronova Biopharma Norge As Lipid compounds for use in cosmetic products, as food supplement or as a medicament
KR101783817B1 (ko) 2009-05-08 2017-10-23 프로노바 바이오파마 너지 에이에스 심혈관 질병, 대사 질병, 및 염증성 질환 분야관련 질병의 치료를 위한 다중 불포화 지방산
TW201138832A (en) 2010-01-20 2011-11-16 Pronova Biopharma Norge As Salicylate fatty acid derivatives
SG10201509127YA (en) * 2010-11-05 2015-12-30 Pronova Biopharma Norge As Methods of treatment using lipid compounds
WO2014132135A2 (en) 2013-02-28 2014-09-04 Pronova Biopharma Norge As Methods of preparing fatty acid derivatives
US11351139B2 (en) * 2013-02-28 2022-06-07 Basf As Composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
WO2016156912A1 (en) 2015-04-01 2016-10-06 Pronova Biopharma Norge As Use of thia oxo compounds for lowering apo c3
AU2016256552B2 (en) 2015-04-28 2021-04-01 Pronova Biopharma Norge As Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis
EP3350165B1 (en) * 2015-09-16 2023-07-26 Organovo, Inc. Farnesoid x receptor agonists and uses thereof
US20190142905A1 (en) * 2016-04-19 2019-05-16 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
MX2019007789A (es) * 2016-12-28 2019-10-21 Modunex Bio Corp Terapia de combinacion para esteatohepatitis no alcoholica (nash) y fibrosis hepatica.
CA3058542A1 (en) * 2017-04-18 2018-10-25 Genfit Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor
IL308604B2 (en) * 2017-12-06 2025-08-01 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
US20220047553A1 (en) * 2018-09-18 2022-02-17 Metacrine, Inc. Farnesoid x receptor agonists for the treatment of disease

Similar Documents

Publication Publication Date Title
TWI852999B (zh) 治療脂肪性肝病及/或脂肪性肝炎的方法
JP2021505591A5 (cg-RX-API-DMAC7.html)
US12440466B2 (en) Fatty acid derivatives for treating non-alcoholic steatohepatitis
CN100352433C (zh) 用于治疗炎症的脂肪醇和脂肪酸酯
RU2019137026A (ru) Сложные эфиры для лечения офтальмологических воспалительных заболеваний
MX366137B (es) Acidos grasos poliinsaturados para el tratamiento de trastornos relacionados a las areas de los trastornos cardiovasculares, metabolicos e inflamatorios.
JP2018515463A5 (cg-RX-API-DMAC7.html)
JP2024095711A (ja) 可溶性グアニル酸シクラーゼ活性化薬としてのアルコキシピラゾール
RU2019113150A (ru) Комбинация композиций, содержащих агонисты fxr, предназначенная для лечения или предупреждения фиброзирующего, цирротического заболевания или нарушения
KR101466617B1 (ko) 오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제
RU2017137960A (ru) Применение тиаоксосоединений для уменьшения содержания аро сз
CL2021000846A1 (es) Compuestos aromáticos y usos farmacéuticos de los mismos
JP6650006B2 (ja) 脂質異常症治療剤
JP2023554524A (ja) 非アルコール性脂肪性肝炎の治療のための酸素含有構造強化脂肪酸を含む組合せ療法
TW202423441A (zh) 治療塵肺病的方法
HK40054971B (en) Method for treating fatty liver disease and/or steatohepatitis
JP2020090448A (ja) アレルギー性結膜炎予防又は治療剤